0
     

Report Added
Report already added
Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027

Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027

The veterinary pain management market is projected to reach USD 2.5 Billion by 2027 from USD 1.8 Billion in 2022, at a CAGR of 6.7% during the forecast period. This market is subsegmented into by Product, Application, Animal, End User, And Region.

“Opioids segment holds second largest share in the veterinary pain management market by drug type in 2021”

The veterinary pain management drugs market is segment into NSAIDs, opioids, local anesthetics, alpha-2 agonists, disease-modifying osteoarthritis drugs, and other drugs on the basis of drug type. In 2021, the opioids segment accounted for a second largest share of the veterinary pain management drugs market.

“Laser therapy device segment holds largest share in the veterinary pain management market by device type in 2021 ”

Based on types of veterinary pain management devices, the market is segmented into laser therapy and electromagnetic field therapy devices. The laser therapy devices segment accounted for the largest share in 2021. Laser therapy is effective in curing a wide range of acute and chronic pain conditions; it targets and cures the cause of pain, ruling out the need for painful invasive surgeries and further use of pain relief drugs. These advantages are expected to drive the growth of laser therapy devices in the veterinary pain management devices market.

“Dog holds the largest share of Companion animal veterinary pain management market in 2021”

Based on animal type, the veterinary pain management market is segmented into companion animals and livestock animals. The companion animals segment accounted for the largest share of the veterinary pain management market in 2021. The large share of this segment can be attributed to the increasing companion animal ownership, growing awareness about animal health among pet owners, and rising pet healthcare expenditure

“China is projected to registered highest growth rate of the APAC veterinary pain management market in 2021”

The China market is estimated to grow at the highest CAGR during the forecast period. The factors such as increasing number of veterinary surgeries, increasing pet insurance, increasing the demand of animal derived factors, and increasing veterinary hospitals and clinics are contributing the growth of China market in veterinary pain management market during forecast period.

A breakdown of the primary participants (supply-side) for the veterinary pain management market referred to for this report is provided below:

•By Company Type: Tier 1–45%, Tier 2–34%, and Tier 3–21%
•By Designation: C-level–26%, Director Level–30%, and Others–44%
•By Region: North America–35%, Europe–32%, Asia Pacific–25%, Latin America- 6%, and Middle East and Africa– 2%

The prominent players in the veterinary pain management market are Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Elanco Animal Health Incorporated (US), Merck & Co., Inc. (US), Dechra Pharmaceuticals (UK), Vetoquinol (France), SeQuent Scientific Limited (India), Norbrook Laboratories Limited (Ireland), Ceva Santé Animale (France), Chanelle Pharma (Ireland), and K-Laser USA (US). New product launches and acquisitions were the major strategies adopted by these payers to maintain their positions in the veterinary pain management market.

Research Coverage:
The market study covers the veterinary pain management market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product, application type, animal type, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the veterinary pain management market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.
Table of Contents

1INTRODUCTION40
1.1STUDY OBJECTIVES40
1.2MARKET DEFINITION40
1.2.1INCLUSIONS & EXCLUSIONS41
1.3MARKET SCOPE42
1.3.1MARKETS COVERED42
FIGURE 1VETERINARY PAIN MANAGEMENT MARKET SEGMENTATION42
1.3.2REGIONAL MARKETS COVERED43
1.3.3YEARS CONSIDERED43
1.4CURRENCY CONSIDERED44
TABLE 1STANDARD CURRENCY CONVERSION RATES44
1.5LIMITATIONS44
1.6STAKEHOLDERS44
1.7SUMMARY OF CHANGES45
2RESEARCH METHODOLOGY46
2.1RESEARCH APPROACH46
2.2RESEARCH METHODOLOGY DESIGN46
FIGURE 2VETERINARY PAIN MANAGEMENT MARKET: RESEARCH DESIGN46
2.2.1SECONDARY RESEARCH47
2.2.1.1Key data from secondary sources48
2.2.2PRIMARY DATA49
FIGURE 3PRIMARY SOURCES49
2.2.2.1Key data from primary sources50
2.2.2.2Insights from primary experts51
FIGURE 4BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS51
FIGURE 5BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION52
FIGURE 6BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION52
2.3MARKET SIZE ESTIMATION53
FIGURE 7SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS54
FIGURE 8SUPPLY-SIDE MARKET SIZE ESTIMATION: VETERINARY PAIN MANAGEMENT MARKET (2021)54
FIGURE 9TOP-DOWN APPROACH55
FIGURE 10CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES56
FIGURE 11CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS57

2.4MARKET BREAKDOWN & DATA TRIANGULATION58
FIGURE 12DATA TRIANGULATION METHODOLOGY58
2.5MARKET SHARE ESTIMATION59
2.6ASSUMPTIONS59
2.7RISK ASSESSMENT59
3EXECUTIVE SUMMARY60
FIGURE 13VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)60
FIGURE 14VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)61
FIGURE 15VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)61
FIGURE 16VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)62
FIGURE 17VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)63
FIGURE 18VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2022 VS. 2027 (USD MILLION)63
FIGURE 19VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)64
FIGURE 20GEOGRAPHICAL SNAPSHOT OF VETERINARY PAIN MANAGEMENT MARKET65
4PREMIUM INSIGHTS66
4.1VETERINARY PAIN MANAGEMENT MARKET OVERVIEW66
FIGURE 21GROWTH IN COMPANION ANIMAL ADOPTION AND INCREASING PREVALENCE OF ANIMAL DISEASES TO DRIVE MARKET GROWTH66
4.2VETERINARY PAIN MANAGEMENT MARKET: REGIONAL MIX67
FIGURE 22ASIA PACIFIC MARKET TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD67
4.3ASIA PACIFIC: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT AND COUNTRY (2021)68
FIGURE 23VETERINARY PAIN MANAGEMENT DRUGS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 202168
4.4VETERINARY PAIN MANAGEMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES69
FIGURE 24CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD69
4.5VETERINARY PAIN MANAGEMENT MARKET: DEVELOPED VS. DEVELOPING MARKETS70
FIGURE 25DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD70
5MARKET OVERVIEW71
5.1INTRODUCTION71
5.2MARKET DYNAMICS71
FIGURE 26VETERINARY PAIN MANAGEMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES71
5.2.1MARKET DRIVERS72
5.2.1.1Growth in companion animal population72
TABLE 2PET POPULATION, BY ANIMAL, 2014–2020 (MILLION)73
5.2.1.2Increasing consumption of meat & milk73
TABLE 3PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK IN DEVELOPED AND DEVELOPING COUNTRIES73
TABLE 4ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)74
5.2.1.3Growing prevalence of diseases74
5.2.1.4Increasing number of veterinary practitioners in developed economies75
TABLE 5NUMBER OF VETERINARIANS AND PARAVETERINARIANS IN DEVELOPED COUNTRIES, 2012–202075
5.2.2MARKET RESTRAINTS75
5.2.2.1Rising pet care costs75
FIGURE 27US: BASIC ANNUAL EXPENSES FOR DOGS AND CATS, 202176
5.2.3MARKET OPPORTUNITIES76
5.2.3.1Increasing popularity of non-conventional and non-pharmaceutical treatment techniques76
5.2.3.2Untapped emerging markets77
5.2.4MARKET CHALLENGES77
5.2.4.1Stringent regulatory process77
5.3TECHNOLOGY ANALYSIS77
5.3.1KEY TECHNOLOGIES77
5.3.1.1Development of low-level light therapy/laser therapy/photobiomodulation77
TABLE 6SOME COMMERCIALLY AVAILABLE LASER THERAPY INSTRUMENTS78
5.4ECOSYSTEM ANALYSIS78
TABLE 7VETERINARY PAIN MANAGEMENT MARKET: ECOSYSTEM MAPPING78
FIGURE 28VETERINARY PAIN MANAGEMENT MARKET: ECOSYSTEM MARKET MAP79
5.5AVERAGE SELLING PRICE TRENDS80
5.5.1AVERAGE SELLING PRICE OF KEY PLAYERS, BY APPLICATION80
TABLE 8PRICING ANALYSIS OF PAIN MANAGEMENT PRODUCTS OFFERED BY LEADING PLAYERS (USD)80
5.6PATENT ANALYSIS80
5.6.1PATENT PUBLICATION TRENDS FOR VETERINARY PAIN MANAGEMENT PRODUCTS80
FIGURE 29PATENT PUBLICATION TRENDS (JANUARY 2012–AUGUST 2022)81
5.6.2INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS81
FIGURE 30TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY PAIN MANAGEMENT (JANUARY 2012–JULY 2022)82
FIGURE 31TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY PAIN MANAGEMENT PATENTS (JANUARY 2012–JULY 2022)83
5.7VALUE CHAIN ANALYSIS83
FIGURE 32VETERINARY PAIN MANAGEMENT MARKET: VALUE CHAIN ANALYSIS84

5.8SUPPLY CHAIN ANALYSIS84
FIGURE 33VETERINARY PAIN MANAGEMENT MARKET: SUPPLY CHAIN ANALYSIS85
5.9PORTER’S FIVE FORCES ANALYSIS86
FIGURE 34VETERINARY PAIN MANAGEMENT MARKET: PORTER’S FIVE FORCES ANALYSIS86
TABLE 9VETERINARY PAIN MANAGEMENT MARKET: PORTER’S FIVE FORCES ANALYSIS86
5.9.1THREAT FROM NEW ENTRANTS87
5.9.2THREAT FROM SUBSTITUTES87
5.9.3BARGAINING POWER OF SUPPLIERS88
5.9.4BARGAINING POWER OF BUYERS88
5.9.5INTENSITY OF COMPETITIVE RIVALRY88
5.10KEY CONFERENCES & EVENTS DURING 2022–202389
TABLE 10VETERINARY PAIN MANAGEMENT MARKET: DETAILED LIST OF CONFERENCES & EVENTS89
5.11KEY STAKEHOLDERS & BUYING CRITERIA90
5.11.1KEY STAKEHOLDERS IN BUYING PROCESS90
FIGURE 35INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS90
TABLE 11INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS90
5.11.2BUYING CRITERIA91
FIGURE 36KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS91
TABLE 12KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS91
5.12TRENDS AND DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES92
FIGURE 37VETERINARY PAIN MANAGEMENT MARKET: TRENDS AND DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES92
5.13TRADE ANALYSIS92
5.14INDUSTRY TRENDS92
5.14.1ADOPTION OF REGENERATIVE MEDICINE92
5.15REGULATORY ANALYSIS93
5.15.1REGULATORY LANDSCAPE93
FIGURE 38DEVELOPMENT AND APPROVAL PROCESS FOR ANIMAL PHARMACEUTICAL PRODUCTS95
5.15.2REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS95
5.15.2.1US95
TABLE 13NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS95
5.15.2.2Europe97
TABLE 14EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS97
5.15.2.3Rest of the world98
TABLE 15REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS98

6VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT99
6.1INTRODUCTION100
TABLE 16VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT,
2020–2027 (USD MILLION)100
6.2DRUGS100
6.2.1DRUGS MARKET, BY TYPE100
TABLE 17VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)101
TABLE 18VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)101
6.2.1.1NSAIDs102
6.2.1.1.1Extensive use of NSAIDS to control pain and inflammation in animals to drive market102
TABLE 19VETERINARY PAIN MANAGEMENT DRUGS MARKET FOR NSAIDS, BY COUNTRY, 2020–2027 (USD MILLION)102
6.2.1.2Opioids103
6.2.1.2.1Advantages of opioids such as remarkable safety profile, high efficacy, and reversibility to promote adoption103
TABLE 20VETERINARY PAIN MANAGEMENT DRUGS MARKET FOR OPIOIDS, BY COUNTRY, 2020–2027 (USD MILLION)103
6.2.1.3Local anesthetics104
6.2.1.3.1Ability of local anesthetics to minimize post-operative pain in animals to support demand104
TABLE 21VETERINARY PAIN MANAGEMENT DRUGS MARKET FOR LOCAL ANESTHETICS, BY COUNTRY, 2020–2027 (USD MILLION)104
6.2.1.4Alpha-2 agonists105
6.2.1.4.1Excessive sedation caused and loss of muscle coordination may limit use of alpha-2 agonists105
TABLE 22VETERINARY PAIN MANAGEMENT DRUGS MARKET FOR ALPHA-2 AGONISTS, BY COUNTRY, 2020–2027 (USD MILLION)105
6.2.1.5Disease-modifying osteoarthritis drugs106
6.2.1.5.1Ability of DMOADs to stabilize joint membranes, help with joint cartilage repair, and improve joint lubrication to increase adoption106
TABLE 23VETERINARY PAIN MANAGEMENT DRUGS MARKET FOR DISEASE-MODIFYING OSTEOARTHRITIS DRUGS, BY COUNTRY, 2020–2027 (USD MILLION)106
6.2.1.6Other drugs107
TABLE 24OTHER VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)107
6.2.2DRUGS MARKET, BY ROUTE OF ADMINISTRATION108
TABLE 25ROUTES OF ADMINISTRATION OF MAJOR VETERINARY PAIN MANAGEMENT DRUGS108
TABLE 26VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)109
6.2.2.1Oral109
6.2.2.1.1Affordability and ability to treat wide range of diseases to drive demand for oral drugs109
TABLE 27ORAL VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)110
6.2.2.2Parenteral110
6.2.2.2.1Advantages such as injecting drugs at affected sites and no direct interaction with gastrointestinal tract make parenteral drugs popular110
TABLE 28PARENTERAL VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)111
6.2.2.3Topical111
6.2.2.3.1Temporary effects of topical drugs compared with oral and parenteral drugs to hinder market growth111
TABLE 29TOPICAL VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)112
6.3DEVICES112
TABLE 30VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)113
TABLE 31VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)113
6.3.1LASER THERAPY DEVICES114
6.3.1.1Effectiveness of laser therapy devices in curing wide range of acute and chronic pain conditions in animals to drive growth114
TABLE 32VETERINARY PAIN MANAGEMENT LASER THERAPY DEVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)114
6.3.2ELECTROMAGNETIC THERAPY DEVICES115
6.3.2.1Adoption of electromagnetic therapy devices to grow in coming years due to their effectiveness and ease of handling115
TABLE 33VETERINARY PAIN MANAGEMENT ELECTROMAGNETIC THERAPY DEVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)115
7VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION116
7.1INTRODUCTION117
TABLE 34VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)117
7.2JOINT PAIN117
TABLE 35VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)118
TABLE 36VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY COUNTRY, 2020–2027 (USD MILLION)118
7.2.1OSTEOARTHRITIS119
7.2.1.1Growing prevalence of osteoarthritis in companion animals to drive market growth119
TABLE 37VETERINARY PAIN MANAGEMENT MARKET FOR OSTEOARTHRITIS, BY COUNTRY, 2020–2027 (USD MILLION)120
7.2.2MUSCULOSKELETAL DISORDERS120
7.2.2.1Rising number of veterinary visits to drive adoption of pain management drugs for musculoskeletal disorders120
TABLE 38VETERINARY PAIN MANAGEMENT MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)121
7.3POST-OPERATIVE PAIN121
7.3.1INCREASING NUMBER OF ANIMALS UNDERGOING SURGERY TO DRIVE GROWTH IN THIS MARKET SEGMENT121
TABLE 39VETERINARY PAIN MANAGEMENT MARKET FOR POST-OPERATIVE PAIN, BY COUNTRY, 2020–2027 (USD MILLION)122
7.4CANCER122
7.4.1NEED FOR PAIN MANAGEMENT AT ALL STAGES OF CANCER TREATMENT TO SUPPORT GROWTH122
TABLE 40VETERINARY PAIN MANAGEMENT MARKET FOR CANCER, BY COUNTRY, 2020–2027 (USD MILLION)123
7.5OTHER APPLICATIONS124
TABLE 41VETERINARY PAIN MANAGEMENT MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)124
8VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE125
8.1INTRODUCTION126
TABLE 42VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)126
TABLE 43VETERINARY PAIN MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)126
8.2COMPANION ANIMALS127
TABLE 44VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)127
TABLE 45VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)128
8.2.1DOGS128
8.2.1.1Higher adoption rate of dogs than other companion animals to drive market growth128
TABLE 46DOG POPULATION, BY COUNTRY, 2012–2020 (MILLION)129
TABLE 47VETERINARY PAIN MANAGEMENT MARKET FOR DOGS, BY COUNTRY, 2020–2027 (USD MILLION)130
8.2.2CATS130
8.2.2.1Growing pet cat population to support growth130
TABLE 48CAT POPULATION, BY COUNTRY, 2012–2020 (MILLION)131
TABLE 49VETERINARY PAIN MANAGEMENT MARKET FOR CATS, BY COUNTRY, 2020–2027 (USD MILLION)131
8.2.3HORSES132
8.2.3.1Growing equine health awareness to drive growth132
TABLE 50EQUINE POPULATION, BY COUNTRY, 2012–2019 (THOUSAND)132
TABLE 51VETERINARY PAIN MANAGEMENT MARKET FOR HORSES, BY COUNTRY, 2020–2027 (USD MILLION)133
8.2.4OTHER COMPANION ANIMALS133
TABLE 52VETERINARY PAIN MANAGEMENT MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)134
8.3LIVESTOCK ANIMALS134
TABLE 53VETERINARY PAIN MANAGEMENT FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)135
TABLE 54VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)135
8.3.1CATTLE136
8.3.1.1Growing consumption of meat to support market growth136
TABLE 55CATTLE POPULATION, BY COUNTRY, 2012–2019 (MILLION)137
TABLE 56VETERINARY PAIN MANAGEMENT MARKET FOR CATTLE, BY COUNTRY, 2020–2027 (USD MILLION)137
8.3.2SWINE138
8.3.2.1Growing incidence of infectious diseases to drive market growth138
TABLE 57SWINE POPULATION, BY COUNTRY, 2012–2019 (MILLION)139
TABLE 58VETERINARY PAIN MANAGEMENT MARKET FOR SWINE, BY COUNTRY, 2020–2027 (USD MILLION)139
8.3.3OTHER LIVESTOCK ANIMALS140
TABLE 59VETERINARY PAIN MANAGEMENT MARKET FOR OTHER LIVESTOCK ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)140
9VETERINARY PAIN MANAGEMENT MARKET, BY END USER141
9.1INTRODUCTION142
TABLE 60VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)142
9.2VETERINARY HOSPITALS142
9.2.1GROWING INVESTMENTS IN EXPANDING VETERINARY HOSPITALS TO DRIVE MARKET GROWTH142
TABLE 61VETERINARY PAIN MANAGEMENT MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)143
9.3VETERINARY CLINICS143
9.3.1GROWING NUMBER OF PATIENT VISITS TO PROMOTE GROWTH IN THIS MARKET SEGMENT143
TABLE 62VETERINARY PAIN MANAGEMENT MARKET FOR CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)144
9.4PHARMACIES & DRUG STORES144
9.4.1CONVENIENCE AND EASY ACCESS TO VETERINARY DRUGS TO MAKE PHARMACIES POPULAR ALTERNATIVES144
TABLE 63VETERINARY PAIN MANAGEMENT MARKET FOR PHARMACIES & DRUG STORES, BY COUNTRY, 2020–2027 (USD MILLION)145
10VETERINARY PAIN MANAGEMENT MARKET, BY REGION146
10.1INTRODUCTION147
FIGURE 39VETERINARY PAIN MANAGEMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES147
TABLE 64VETERINARY PAIN MANAGEMENT MARKET, BY REGION, 2020–2027 (USD MILLION)148
10.2NORTH AMERICA148
FIGURE 40NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET SNAPSHOT149
TABLE 65NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)149
TABLE 66NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)150
TABLE 67NORTH AMERICA: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)150
TABLE 68NORTH AMERICA: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)150
TABLE 69NORTH AMERICA: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)151
TABLE 70NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)151
TABLE 71NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)151
TABLE 72NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)152
TABLE 73NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)152
TABLE 74NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)152
TABLE 75NORTH AMERICA: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)153
10.2.1US153
10.2.1.1Growing pet ownership to drive market growth153
FIGURE 41US: POPULATION OF DOGS, 2012–2020 (MILLION)153
TABLE 76HEALTHCARE EXPENDITURE ON COMPANION ANIMALS, 2018 VS. 2020154
FIGURE 42NUMBER OF VETERINARIANS IN US, 2016–2020154
TABLE 77US: FOOD-PRODUCING ANIMAL POPULATION, 2001–2019 (MILLION)154
TABLE 78US: NUMBER OF VETERINARIANS IN PRIVATE CLINICAL PRACTICES, 2014–2020155
TABLE 79US: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)155
TABLE 80US: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)155
TABLE 81US: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)156
TABLE 82US: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)156
TABLE 83US: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)156
TABLE 84US: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)157
TABLE 85US: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)157
TABLE 86US: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)157
TABLE 87US: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2020–2027 (USD MILLION)158
TABLE 88US: VETERINARY PAIN MANAGEMENT MARKET, BY END USER,
2020–2027 (USD MILLION)158
10.2.2CANADA158
10.2.2.1Growing pool of skilled veterinarians to support market growth158
FIGURE 43CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION)159
TABLE 89CANADA: LARGE ANIMAL POPULATION, 2001–2019 (MILLION)159
TABLE 90CANADA: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT,
2020–2027 (USD MILLION)160
TABLE 91CANADA: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE,
2020–2027 (USD MILLION)160
TABLE 92CANADA: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)160
TABLE 93CANADA: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)161
TABLE 94CANADA: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)161
TABLE 95CANADA: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)161
TABLE 96CANADA: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)162
TABLE 97CANADA: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)162
TABLE 98CANADA: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)162
TABLE 99CANADA: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)163
10.3EUROPE163
TABLE 100EUROPE: COMPANION POPULATION, 2019 (MILLION)164
TABLE 101EUROPE: LIVESTOCK POPULATION, 2019 (MILLION)164
TABLE 102EUROPE: NUMBER OF VETERINARIANS, 2012–2019165
TABLE 103EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)165
TABLE 104EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)166
TABLE 105EUROPE: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)166
TABLE 106EUROPE: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)166
TABLE 107EUROPE: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)167
TABLE 108EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)167
TABLE 109EUROPE: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)167
TABLE 110EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)168
TABLE 111EUROPE: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)168
TABLE 112EUROPE: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)168
TABLE 113EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)169
10.3.1GERMANY169
10.3.1.1Rising awareness about pet healthcare in Germany to promote market growth169
TABLE 114GERMANY: LIVESTOCK ANIMAL POPULATION, 2016–2019 (MILLION)170
TABLE 115GERMANY: COMPANION ANIMAL POPULATION, 2016–2019 (MILLION)170
TABLE 116GERMANY: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)170
TABLE 117GERMANY: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)171
TABLE 118GERMANY: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)171
TABLE 119GERMANY: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)172
TABLE 120GERMANY: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)172
TABLE 121GERMANY: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)172
TABLE 122GERMANY: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)173
TABLE 123GERMANY: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)173
TABLE 124GERMANY: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)173
TABLE 125GERMANY: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)174
10.3.2FRANCE174
10.3.2.1Favorable government policies promoting export of livestock products to support growth174
TABLE 126FRANCE: PET POPULATION, 2017–2020 (MILLION)174
TABLE 127FRANCE: LIVESTOCK ANIMAL POPULATION, 2016–2019 (MILLION)175
TABLE 128FRANCE: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)175
TABLE 129FRANCE: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)176
TABLE 130FRANCE: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)176
TABLE 131FRANCE: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)177
TABLE 132FRANCE: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)177
TABLE 133FRANCE: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)177
TABLE 134FRANCE: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)178
TABLE 135FRANCE: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)178
TABLE 136FRANCE: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)178
TABLE 137FRANCE: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)179
10.3.3UK179
10.3.3.1Increasing availability of animal health insurance to aid growth179
TABLE 138UK: PET POPULATION, 2017–2020 (MILLION)180
TABLE 139UK: LIVESTOCK ANIMAL POPULATION, 2016–2019 (MILLION)180
TABLE 140UK: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)180
TABLE 141UK: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)181
TABLE 142UK: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)181
TABLE 143UK: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)182
TABLE 144UK: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)182
TABLE 145UK: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)182
TABLE 146UK: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)183
TABLE 147UK: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)183
TABLE 148UK: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)183
TABLE 149UK: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)184
10.3.4ITALY184
10.3.4.1Growing demand for pork to propel market growth in Italy184
TABLE 150ITALY: PET POPULATION, 2017–2020 (MILLION)184
TABLE 151ITALY: LIVESTOCK ANIMAL POPULATION, 2016–2019 (MILLION)185
TABLE 152ITALY: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)185
TABLE 153ITALY: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)185
TABLE 154ITALY: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)186
TABLE 155ITALY: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)186
TABLE 156ITALY: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)186
TABLE 157ITALY: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)187
TABLE 158ITALY: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)187
TABLE 159ITALY: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)187
TABLE 160ITALY: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)188
TABLE 161ITALY: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)188
10.3.5SPAIN188
10.3.5.1Rising livestock population to make Spain a relatively large market188
TABLE 162SPAIN: PET POPULATION, 2017–2020 (MILLION)189
TABLE 163SPAIN: LIVESTOCK ANIMAL POPULATION, 2016–2019 (MILLION)189
TABLE 164SPAIN: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)190
TABLE 165SPAIN: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)190
TABLE 166SPAIN: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)190
TABLE 167SPAIN: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)191
TABLE 168SPAIN: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)191
TABLE 169SPAIN: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)191
TABLE 170SPAIN: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)192
TABLE 171SPAIN: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)192
TABLE 172SPAIN: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)192
TABLE 173SPAIN: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)193
10.3.6REST OF EUROPE (ROE)193
TABLE 174REST OF EUROPE: COMPANION ANIMAL OWNERSHIP, BY COUNTRY, 2019 (MILLION)193
TABLE 175REST OF EUROPE: LIVESTOCK POPULATION, BY COUNTRY, 2019 (MILLION)194
TABLE 176REST OF EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT, 2020–2027 (USD MILLION)194
TABLE 177REST OF EUROPE: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION)194
TABLE 178REST OF EUROPE: VETERINARY PAIN MANAGEMENT DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)195
TABLE 179REST OF EUROPE: VETERINARY PAIN MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)195
TABLE 180REST OF EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY APPLICATION, 2020–2027 (USD MILLION)195
TABLE 181REST OF EUROPE: VETERINARY PAIN MANAGEMENT MARKET FOR JOINT PAIN, BY TYPE, 2020–2027 (USD MILLION)196
TABLE 182REST OF EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)196
TABLE 183REST OF EUROPE: VETERINARY PAIN MANAGEMENT MARKET FOR COMPANION ANIMALS, BY TYPE, 2020–2027 (USD MILLION)196
TABLE 184REST OF EUROPE: VETERINARY PAIN MANAGEMENT MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2020–2027 (USD MILLION)197
TABLE 185REST OF EUROPE: VETERINARY PAIN MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)197

Report Title: Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Venom Based Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Animal Type (Snake, Spider, Bee, Others), By Source (Whole Venom, Synthetic, Recombinant, Others), By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others), By Company and By Region

Venom Based Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Animal Type (Snake, Spider, Bee, Others), By Source (Whole Venom, Synthetic, Recombinant, Others), By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others), By Company and By Region

Phage Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Bacteria Type (Salmonella, Bacteriophage, Streptococcus, E.Coli, Others), By Product (Oral Consumption, External Consumption, Surgical Treatment), By Application (Human Medicines, Veterinary Sciences, Food & Beverage, Others), and By Region

Phage Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Bacteria Type (Salmonella, Bacteriophage, Streptococcus, E.Coli, Others), By Product (Oral Consumption, External Consumption, Surgical Treatment), By Application (Human Medicines, Veterinary Sciences, Food & Beverage, Others), and By Region

Natural Killer Cells Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Natural Killer Cell Therapies v/s Natural Killer Cell Directed Antibodies), By Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, Others), By End User (Hospitals & Clinics, Academic & Research Institutions, Others), By Region

Natural Killer Cells Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented by Type (Natural Killer Cell Therapies v/s Natural Killer Cell Directed Antibodies), By Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, Others), By End User (Hospitals & Clinics, Academic & Research Institutions, Others), By Region

Medication Reminder Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Type (Mobile Phone Reminders, In-Home Electronic Devices, Portable Reminder Devices), By End User (Homecare, Hospitals & Clinics, Others), By Company and By Region

Medication Reminder Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (Mobile Phone Reminders, In-Home Electronic Devices, Portable Reminder Devices), By End User (Homecare, Hospitals & Clinics, Others), By Company and By Region

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region

Hand, Foot, and Mouth Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Drug Type (Pain Relievers, Non-Steroidal Anti-inflammatory Drugs, Nucleoside Analogue Antivirals), By Route of Administration (Topical, Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region

Hand, Foot, and Mouth Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Drug Type (Pain Relievers, Non-Steroidal Anti-inflammatory Drugs, Nucleoside Analogue Antivirals), By Route of Administration (Topical, Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region